Adoptive T cell therapy of solid cancers.
The development of immune-based approaches for the treatment of cancer has been actively investigated for many years. One strategy that has emerged as a potentially effective strategy for the treatment of aggressive established malignancies is adoptive T cell therapy. The power of this approach has been repeatedly observed in preclinical animal models. However, moving from homogeneous animal models to the heterogeneous human clinical setting has been very difficult. It is only in recent times that we have been able to pinpoint the problems of the clinical translation of adoptive T cell therapy. Some of the major problems are sources of tumor-specific T cells, ex vivo expansion, persistence, and anti-tumor activity. This review overviews the nature of these problems and some of the emerging solutions.
Knutson
Keith L
KL
Mayo Clinic College of Medicine, 342D Guggenheim, 200 First St SW, Mayo Clinic, Rochester, MN 55905, USA.
Wagner
Wolfgang
W
Disis
Mary L
ML
D000818:Animals; D019496:Cancer Vaccines / Q000276:immunology*; D004195:Disease Models, Animal; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D009369:Neoplasms / Q000276:immunology / Q000628:therapy; D013601:T-Lymphocytes / Q000276:immunology*
D019496:Cancer Vaccines